Clinical trials for rare lung diseases: Lessons from lymphangioleiomyomatosis

Lymphatic Research and Biology

Volumn 8, Issue 1, 2010, Pages 71-79

  Kinder, Brent ^a   McCormack, Francis X ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIESTROGEN; AROMATASE INHIBITOR; BETA INTERFERON; BEVACIZUMAB; DOXYCYCLINE; EVEROLIMUS; GESTAGEN; GONADORELIN AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MARIMASTAT; METALLOPROTEINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; ROSCOVITINE; SORAFENIB; SUNITINIB;

ANGIOMYOLIPOMA; CANCER CHEMOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG TARGETING; ENZYME ACTIVITY; GENE MUTATION; HUMAN; LUNG DISEASE; LYMPHANGIOGENESIS; LYMPHANGIOLEIOMYOMATOSIS; OFF LABEL DRUG USE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; RARE DISEASE; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TARGET CELL;

CLINICAL TRIALS AS TOPIC; HUMANS; LUNG DISEASES; LYMPHANGIOLEIOMYOMATOSIS; RARE DISEASES;

EID: 77949847927     PISSN: 15396851     EISSN: None     Source Type: Journal    
DOI: 10.1089/lrb.2009.0027     Document Type: Review

References (39)

1. McCormack FX. Lymphangioleiomyomatosis: A clinical update. Chest 1 2008;33:507-516.
2. Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: Characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006;173:105-111.
3. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP. Molecular pathogenesis of lymphangioleiomyomatosis: Lessons learned from orphans. Am J Respir Cell Mol Biol 2007;36:398-408.
4. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-151.
5. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-1356.
6. Ito N, Rubin GM. gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell 1999;96:529-539.
7. Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001;105:357-368.
8. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 2001;105:345-355.
9. Yu J, Henske EP. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase ras homologue enriched in brain. Cancer Res 2006; 66:9461-9466.
10. Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 2004;286: L694-700.
11. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC 1. J Biol Chem 2009;284:8023-8032.
12. Thoreen CC, Sabatini DM. Rapamycin inhibits mTORC1, but not completely. Autophagy 2009;5:725-726.
13. Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA 2009;106:2635-2640.
14. Zhe X, Yang Y, Jakkaraju S, Schuger L. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: Potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol 2003;28: 504-511.
15. Hayashi T, Fleming MV, Stetler-Stevenson WG, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis. Hum Pathol 1997;28:1071-1078.
16. Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000;124:267-275.
17. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19:6642-6650.
18. Bittmann I, Dose TB, Muller C, Dienemann H, Vogelmeir C. Lymphagioleiomyomatosis: Recurrence after single lung transplantations. Hum Pathol 1997;26:1420-1423.
19. Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: Genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167:976-982.
20. Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 2003;38:376-381.
21. Longacre TA, Hendrickson MR, Kapp DS, Teng NN. Lymphangioleiomyomatosis of the uterus simulating high-stage endometrial stromal sarcoma. Gynecol Oncol 1996;63:404-410.
22. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004;101:17462-17467.
23. Berner A, Franzen S, Heilo A. Fine needle aspiration cytology as a diagnostic approach to lymphangioleiomyomatosis. A case report. Acta Cytol 1997;41:877-879.
24. Kamitani T, Yabuuchi H, Soeda H, et al. A case of lymphangioleiomyomatosis affecting the supraclavicular lymph nodes. J Comput Assist Tomogr 2006;30:279-282.
25. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis- mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 2005;29:1356-1366.
26. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis in lymphangioleiomyomatosis: Its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol 2004;28:1007-1016.
27. Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006;4:143-152.
28. Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008;358:199-200.
29. Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006;34:473-480.
30. Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007;71:771-777.
31. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007;98:726-733.
32. Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 2005;57:67-75.
33. Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009;135:1293-1300.
34. Schmithorst VJ, Altes TA, Young LR, et al. Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: Initial results in lymphangioleiomyomatosis. AJR Am J Roentgenol 2009;192:1037-1044.
35. Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: Opportunities, challenges, and solutions. Mol Genet Metab 2009;96:20-26.
36. Taveira-DaSilva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Control 2006;13:276-285.
37. Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008;358:200-203.
38. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-2666.
39. Kinder BW, Sherman AC, Young LR, Hagaman GT, Opresco N, Byrnes S, McCormack FX. Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis. Respir Med 2009; December 3. Epub ahead of print.